Zafirlukast - AstraZeneca
Alternative Names: Accolate; Accolate SR; Accoleit; Aeronix; Azimax; ICI 204219; Olmoran; Respix®; Vanticon; ZafirstLatest Information Update: 05 Nov 2023
At a glance
- Originator AstraZeneca
- Developer Quercis Pharma; Western New England University
- Class Antiallergics; Antiasthmatics; Tosyl compounds
- Mechanism of Action Isomerase inhibitors; Leukotriene D4 receptor antagonists; Leukotriene E4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Asthma
- Preclinical Amyotrophic lateral sclerosis; COVID 2019 infections; Neurological disorders
Most Recent Events
- 19 May 2021 Zafirlukast licensed to Quercis Pharma worldwide for the treatment of several indications, including COVID-19, Amyotrophic Lateral Sclerosis (ALS), and neurological disorders
- 19 May 2021 Western New England University has patent protection for zafirlukast
- 19 May 2021 Preclinical trials in Amyotrophic lateral sclerosis in USA, Switzerland (unspecified route) prior to May 2021